Skip to main navigation Skip to search Skip to main content

PROLONGED THERAPY OF HEPATITIS DELTA FOR 96 WEEKS WITH PEGYLATED-INTERFERON-α-2a PLUS TENOFOVIR OR PLACEBO DOES NOT PREVENT HDV RNA RELAPSE AFTER TREATMENT: The Hidit-2 Study

  • HIDIT-2 Study Grp

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageEnglish
Pages (from-to)S2-S3
Number of pages2
JournalJournal of Hepatology
Volume60
Issue number1
DOIs
Publication statusPublished - Apr 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this